Which types of cancer is Bevacizumab primarily used to treat?

Which types of cancer is Bevacizumab primarily used to treat?

• A. Breast, stomach, and ovarian cancers
• B. Colon, lung, glioblastoma, and renal cancers
• C. Prostate, pancreatic, and liver cancers
• D. Thyroid, bone, and melanoma cancers

Answer: (B)

Bevacizumab is primarily used to treat various types of cancers, particularly those that are characterized by their susceptibility to angiogenesis, which is the formation of new blood vessels that tumors need for growth. In this context, colon, lung, glioblastoma, and renal cancers are well-established indications for Bevacizumab. Colorectal cancer is one of the primary indications, as Bevacizumab has been shown to improve survival rates when used in combination with chemotherapy. In lung cancer, especially non-small cell lung cancer, Bevacizumab is also utilized as it helps to limit the tumor's blood supply, thereby inhibiting growth. Similarly, in glioblastoma multiforme, a particularly aggressive brain tumor, Bevacizumab has been approved for use in patients with recurrent disease, primarily to manage symptoms related to tumor-associated edema. Lastly, in renal cell carcinoma, Bevacizumab has demonstrated effectiveness in certain settings, especially when used in conjunction with other treatments. The other options do include types of cancers, but they are not primarily treated with Bevacizumab. While there may be clinical scenarios where Bevacizumab could be considered for some of those cancers listed in the other choices, it is not the first-line

Bevacizumab is primarily used to treat various types of cancers, particularly those that are characterized by their susceptibility to angiogenesis, which is the formation of new blood vessels that tumors need for growth. In this context, colon, lung, glioblastoma, and renal cancers are well-established indications for Bevacizumab.

Colorectal cancer is one of the primary indications, as Bevacizumab has been shown to improve survival rates when used in combination with chemotherapy. In lung cancer, especially non-small cell lung cancer, Bevacizumab is also utilized as it helps to limit the tumor's blood supply, thereby inhibiting growth. Similarly, in glioblastoma multiforme, a particularly aggressive brain tumor, Bevacizumab has been approved for use in patients with recurrent disease, primarily to manage symptoms related to tumor-associated edema. Lastly, in renal cell carcinoma, Bevacizumab has demonstrated effectiveness in certain settings, especially when used in conjunction with other treatments.

The other options do include types of cancers, but they are not primarily treated with Bevacizumab. While there may be clinical scenarios where Bevacizumab could be considered for some of those cancers listed in the other choices, it is not the first-line